Trial purpose
Cancer treatment
Tumor type
Haematological
Age
18+
Clinical summary
Summary
Patients with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after receiving either an autologous hematopoietic stem cell transplantation (HSCT) or at least 2 prior systemic chemotherapy regimens and are not candidates for autologous or allogeneic HSCT, will receive 200 mg intravenously (IV) every 3 weeks (Q3W)
Conditions
This trial is treating people with Hodgkin's Lymphoma
Eligibility
Inclusion
- Histologically confirmed diagnosis of relapsed or refractory cHL
-
Relapsed cHL (disease progression after PR or CR to the most recent therapy) or refractory cHL (failure to achieve PR or CR to most recent therapy). Participants will be allocated to one of two cohorts based on the following criteria:
Cohort 1: Relapsed or refractory to prior autologous hematopoietic stem cell transplant (HSCT)
- Has failed to achieve a response or progressed after autologous HSCT
- Is not a candidate for additional autologous or allogeneic HSCT
Cohort 2: Relapsed or refractory to salvage chemotherapy, and has not received prior autologous or allogeneic HSCT
- Is not a candidate for autologous or allogeneic HSCT
- Has received at least 1 prior systemic regimen for cHL
- Measurable disease defined as ≥ 1 2-[18F] fluoro-2-deoxy-D-glucose (FDG)-avid nodal lesion that is > 1.5 cm in the longest diameter, or ≥ 1 FDG-avid extra-nodal lesion (eg, hepatic nodules) that is > 1 cm in the longest diameter
- Eastern Cancer Oncology Group (ECOG) performance status of 0 or 1
Exclusion
- Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma
- Prior allogeneic hematopoietic stem cell transplantation
- Prior therapy targeting PD-1 , PD-L1,PD-L2, or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) pathways
- Active autoimmune disease or history of autoimmune disease that may relapse
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Inclusion
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have certain types of non-cancer medical conditions.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
BeiGene Australia Pty Ltd,Lymphoma Study Association
Scientific Title
A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information